StreetInsider.com News Articles

StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 12 Jun 2026 16:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Savara Announces New Employment Inducement Grant http://www.streetinsider.com/Press+Releases/Savara+Announces+New+Employment+Inducement+Grant/26640599.html <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com&esheet=54552828&newsitemid=20260612214793&lan=en-US&anchor=Savara+Inc.&index=1&md5=d1e64fc35d93b71ddb9b518d04d53b83" shape="rect">Savara Inc.</a> (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. </p><p> On June 11, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase 36,500 shares of the Company’s common stock, restricted stock units (RSUs) covering 42,500 shares of the Company’s common stock, and performance stock units (PSUs) covering 8,000 shares of the Company’s common stock. These equity http://www.streetinsider.com/Press+Releases/Savara+Announces+New+Employment+Inducement+Grant/26640599.html Fri, 12 Jun 2026 16:05:00 -0400 O.01272850 SVRA Savara Announces New Employment Inducement Grant http://www.streetinsider.com/Press+Releases/Savara+Announces+New+Employment+Inducement+Grant/26640599.html <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com&esheet=54552828&newsitemid=20260612214793&lan=en-US&anchor=Savara+Inc.&index=1&md5=d1e64fc35d93b71ddb9b518d04d53b83" shape="rect">Savara Inc.</a> (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. </p><p> On June 11, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase 36,500 shares of the Company’s common stock, restricted stock units (RSUs) covering 42,500 shares of the Company’s common stock, and performance stock units (PSUs) covering 8,000 shares of the Company’s common stock. These equity http://www.streetinsider.com/Press+Releases/Savara+Announces+New+Employment+Inducement+Grant/26640599.html Fri, 12 Jun 2026 16:05:00 -0400 O.01272850 SVRA Savara Announces New Employment Inducement Grant http://www.streetinsider.com/Business+Wire/Savara+Announces+New+Employment+Inducement+Grant/26640599.html <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com&esheet=54552828&newsitemid=20260612214793&lan=en-US&anchor=Savara+Inc.&index=1&md5=d1e64fc35d93b71ddb9b518d04d53b83" shape="rect">Savara Inc.</a> (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. </p><p> On June 11, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase 36,500 shares of the Company’s common stock, restricted stock units (RSUs) covering 42,500 shares of the Company’s common stock, and performance stock units (PSUs) covering 8,000 shares of the Company’s common stock. These equity http://www.streetinsider.com/Business+Wire/Savara+Announces+New+Employment+Inducement+Grant/26640599.html Fri, 12 Jun 2026 16:05:00 -0400 O.01272850 SVRA Savara Announces New Employment Inducement Grant http://www.streetinsider.com/Business+Wire/Savara+Announces+New+Employment+Inducement+Grant/26640599.html <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com&esheet=54552828&newsitemid=20260612214793&lan=en-US&anchor=Savara+Inc.&index=1&md5=d1e64fc35d93b71ddb9b518d04d53b83" shape="rect">Savara Inc.</a> (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. </p><p> On June 11, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase 36,500 shares of the Company’s common stock, restricted stock units (RSUs) covering 42,500 shares of the Company’s common stock, and performance stock units (PSUs) covering 8,000 shares of the Company’s common stock. These equity http://www.streetinsider.com/Business+Wire/Savara+Announces+New+Employment+Inducement+Grant/26640599.html Fri, 12 Jun 2026 16:05:00 -0400 O.01272850 SVRA Form 8-K Savara Inc For: Jun 04 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Savara+Inc++++++++++++++++For%3A+Jun+04/26617548.html si-local-file:///var/storage/secattach/20260608/26617548.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Savara+Inc++++++++++++++++For%3A+Jun+04/26617548.html Mon, 08 Jun 2026 16:16:00 -0400 O.01272850 SVRA Form 8-K Savara Inc For: Jun 04 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Savara+Inc++++++++++++++++For%3A+Jun+04/26617548.html si-local-file:///var/storage/secattach/20260608/26617548.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Savara+Inc++++++++++++++++For%3A+Jun+04/26617548.html Mon, 08 Jun 2026 16:16:00 -0400 O.01272850 SVRA Savara names Robert Lutz as chief operating and financial officer http://www.streetinsider.com/Corporate+News/Savara+names+Robert+Lutz+as+chief+operating+and+financial+officer/26617232.html <p>Savara Inc. (NASDAQ: SVRA) announced that Dave Lowrance will step down as chief financial and administrative officer effective July 15, 2026, for health-related reasons. The clinical-stage biopharmaceutical company said Robert Lutz will assume the combined role of chief operating and financial officer.</p><p>Lowrance served in his role for nearly ten years, guiding the company through capital raises, its Nasdaq listing, and advancing its late-stage pipeline. He will remain available to the company in an advisory capacity following his departure.</p><p>Lutz has served as Savara's chief operating officer since February 2023. He previously held chief financial and business officer positions at iBio Inc. http://www.streetinsider.com/Corporate+News/Savara+names+Robert+Lutz+as+chief+operating+and+financial+officer/26617232.html Mon, 08 Jun 2026 16:05:33 -0400 SVRA Savara names Robert Lutz as chief operating and financial officer http://www.streetinsider.com/Management+Changes/Savara+names+Robert+Lutz+as+chief+operating+and+financial+officer/26617232.html <p>Savara Inc. (NASDAQ: SVRA) announced that Dave Lowrance will step down as chief financial and administrative officer effective July 15, 2026, for health-related reasons. The clinical-stage biopharmaceutical company said Robert Lutz will assume the combined role of chief operating and financial officer.</p><p>Lowrance served in his role for nearly ten years, guiding the company through capital raises, its Nasdaq listing, and advancing its late-stage pipeline. He will remain available to the company in an advisory capacity following his departure.</p><p>Lutz has served as Savara's chief operating officer since February 2023. He previously held chief financial and business officer positions at iBio Inc. http://www.streetinsider.com/Management+Changes/Savara+names+Robert+Lutz+as+chief+operating+and+financial+officer/26617232.html Mon, 08 Jun 2026 16:05:33 -0400 SVRA Savara Announces Chief Financial and Administrative Officer Transition http://www.streetinsider.com/Press+Releases/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html <p class="bwalignc"> <i>-- Dave Lowrance to Step Down as Chief Financial and Administrative Officer --</i> </p><p class="bwalignc"> <i>-- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=Savara+Inc.&index=1&md5=fd315673be183a0a0a21a0d8d4f2e327" shape="rect">Savara Inc.</a> (Nasdaq: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=SVRA&index=2&md5=c334f87372219b3a62213808dc7dc0cb" shape="rect">SVRA</a>) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of this transition, the financial and administrative responsibilities of the role will be separated going forward. Robert Lutz, http://www.streetinsider.com/Press+Releases/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html Mon, 08 Jun 2026 16:05:00 -0400 A.05438480 A.41475125 A.50213484 O.00674119 O.01272850 O.02190753 O.35924857 SVRA Savara Announces Chief Financial and Administrative Officer Transition http://www.streetinsider.com/Press+Releases/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html <p class="bwalignc"> <i>-- Dave Lowrance to Step Down as Chief Financial and Administrative Officer --</i> </p><p class="bwalignc"> <i>-- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=Savara+Inc.&index=1&md5=fd315673be183a0a0a21a0d8d4f2e327" shape="rect">Savara Inc.</a> (Nasdaq: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=SVRA&index=2&md5=c334f87372219b3a62213808dc7dc0cb" shape="rect">SVRA</a>) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of this transition, the financial and administrative responsibilities of the role will be separated going forward. Robert Lutz, http://www.streetinsider.com/Press+Releases/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html Mon, 08 Jun 2026 16:05:00 -0400 A.05438480 A.41475125 A.50213484 O.00674119 O.01272850 O.02190753 O.35924857 SVRA Savara Announces Chief Financial and Administrative Officer Transition http://www.streetinsider.com/Press+Releases/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html <p class="bwalignc"> <i>-- Dave Lowrance to Step Down as Chief Financial and Administrative Officer --</i> </p><p class="bwalignc"> <i>-- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=Savara+Inc.&index=1&md5=fd315673be183a0a0a21a0d8d4f2e327" shape="rect">Savara Inc.</a> (Nasdaq: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=SVRA&index=2&md5=c334f87372219b3a62213808dc7dc0cb" shape="rect">SVRA</a>) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of this transition, the financial and administrative responsibilities of the role will be separated going forward. Robert Lutz, http://www.streetinsider.com/Press+Releases/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html Mon, 08 Jun 2026 16:05:00 -0400 A.05438480 A.41475125 A.50213484 O.00674119 O.01272850 O.02190753 O.35924857 SVRA Savara Announces Chief Financial and Administrative Officer Transition http://www.streetinsider.com/Press+Releases/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html <p class="bwalignc"> <i>-- Dave Lowrance to Step Down as Chief Financial and Administrative Officer --</i> </p><p class="bwalignc"> <i>-- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=Savara+Inc.&index=1&md5=fd315673be183a0a0a21a0d8d4f2e327" shape="rect">Savara Inc.</a> (Nasdaq: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=SVRA&index=2&md5=c334f87372219b3a62213808dc7dc0cb" shape="rect">SVRA</a>) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of this transition, the financial and administrative responsibilities of the role will be separated going forward. Robert Lutz, http://www.streetinsider.com/Press+Releases/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html Mon, 08 Jun 2026 16:05:00 -0400 A.05438480 A.41475125 A.50213484 O.00674119 O.01272850 O.02190753 O.35924857 SVRA Savara Announces Chief Financial and Administrative Officer Transition http://www.streetinsider.com/Press+Releases/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html <p class="bwalignc"> <i>-- Dave Lowrance to Step Down as Chief Financial and Administrative Officer --</i> </p><p class="bwalignc"> <i>-- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=Savara+Inc.&index=1&md5=fd315673be183a0a0a21a0d8d4f2e327" shape="rect">Savara Inc.</a> (Nasdaq: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=SVRA&index=2&md5=c334f87372219b3a62213808dc7dc0cb" shape="rect">SVRA</a>) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of this transition, the financial and administrative responsibilities of the role will be separated going forward. Robert Lutz, http://www.streetinsider.com/Press+Releases/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html Mon, 08 Jun 2026 16:05:00 -0400 A.05438480 A.41475125 A.50213484 O.00674119 O.01272850 O.02190753 O.35924857 SVRA Savara Announces Chief Financial and Administrative Officer Transition http://www.streetinsider.com/Press+Releases/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html <p class="bwalignc"> <i>-- Dave Lowrance to Step Down as Chief Financial and Administrative Officer --</i> </p><p class="bwalignc"> <i>-- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=Savara+Inc.&index=1&md5=fd315673be183a0a0a21a0d8d4f2e327" shape="rect">Savara Inc.</a> (Nasdaq: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=SVRA&index=2&md5=c334f87372219b3a62213808dc7dc0cb" shape="rect">SVRA</a>) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of this transition, the financial and administrative responsibilities of the role will be separated going forward. Robert Lutz, http://www.streetinsider.com/Press+Releases/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html Mon, 08 Jun 2026 16:05:00 -0400 A.05438480 A.41475125 A.50213484 O.00674119 O.01272850 O.02190753 O.35924857 SVRA Savara Announces Chief Financial and Administrative Officer Transition http://www.streetinsider.com/Press+Releases/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html <p class="bwalignc"> <i>-- Dave Lowrance to Step Down as Chief Financial and Administrative Officer --</i> </p><p class="bwalignc"> <i>-- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=Savara+Inc.&index=1&md5=fd315673be183a0a0a21a0d8d4f2e327" shape="rect">Savara Inc.</a> (Nasdaq: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=SVRA&index=2&md5=c334f87372219b3a62213808dc7dc0cb" shape="rect">SVRA</a>) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of this transition, the financial and administrative responsibilities of the role will be separated going forward. Robert Lutz, http://www.streetinsider.com/Press+Releases/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html Mon, 08 Jun 2026 16:05:00 -0400 A.05438480 A.41475125 A.50213484 O.00674119 O.01272850 O.02190753 O.35924857 SVRA Savara Announces Chief Financial and Administrative Officer Transition http://www.streetinsider.com/Press+Releases/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html <p class="bwalignc"> <i>-- Dave Lowrance to Step Down as Chief Financial and Administrative Officer --</i> </p><p class="bwalignc"> <i>-- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=Savara+Inc.&index=1&md5=fd315673be183a0a0a21a0d8d4f2e327" shape="rect">Savara Inc.</a> (Nasdaq: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=SVRA&index=2&md5=c334f87372219b3a62213808dc7dc0cb" shape="rect">SVRA</a>) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of this transition, the financial and administrative responsibilities of the role will be separated going forward. Robert Lutz, http://www.streetinsider.com/Press+Releases/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html Mon, 08 Jun 2026 16:05:00 -0400 A.05438480 A.41475125 A.50213484 O.00674119 O.01272850 O.02190753 O.35924857 SVRA Savara Announces Chief Financial and Administrative Officer Transition http://www.streetinsider.com/Business+Wire/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html <p class="bwalignc"> <i>-- Dave Lowrance to Step Down as Chief Financial and Administrative Officer --</i> </p><p class="bwalignc"> <i>-- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=Savara+Inc.&index=1&md5=fd315673be183a0a0a21a0d8d4f2e327" shape="rect">Savara Inc.</a> (Nasdaq: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=SVRA&index=2&md5=c334f87372219b3a62213808dc7dc0cb" shape="rect">SVRA</a>) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of this transition, the financial and administrative responsibilities of the role will be separated going forward. Robert Lutz, http://www.streetinsider.com/Business+Wire/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html Mon, 08 Jun 2026 16:05:00 -0400 A.05438480 A.41475125 A.50213484 O.00674119 O.01272850 O.02190753 O.35924857 SVRA Savara Announces Chief Financial and Administrative Officer Transition http://www.streetinsider.com/Business+Wire/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html <p class="bwalignc"> <i>-- Dave Lowrance to Step Down as Chief Financial and Administrative Officer --</i> </p><p class="bwalignc"> <i>-- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=Savara+Inc.&index=1&md5=fd315673be183a0a0a21a0d8d4f2e327" shape="rect">Savara Inc.</a> (Nasdaq: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=SVRA&index=2&md5=c334f87372219b3a62213808dc7dc0cb" shape="rect">SVRA</a>) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of this transition, the financial and administrative responsibilities of the role will be separated going forward. Robert Lutz, http://www.streetinsider.com/Business+Wire/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html Mon, 08 Jun 2026 16:05:00 -0400 A.05438480 A.41475125 A.50213484 O.00674119 O.01272850 O.02190753 O.35924857 SVRA Savara Announces Chief Financial and Administrative Officer Transition http://www.streetinsider.com/Business+Wire/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html <p class="bwalignc"> <i>-- Dave Lowrance to Step Down as Chief Financial and Administrative Officer --</i> </p><p class="bwalignc"> <i>-- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=Savara+Inc.&index=1&md5=fd315673be183a0a0a21a0d8d4f2e327" shape="rect">Savara Inc.</a> (Nasdaq: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=SVRA&index=2&md5=c334f87372219b3a62213808dc7dc0cb" shape="rect">SVRA</a>) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of this transition, the financial and administrative responsibilities of the role will be separated going forward. Robert Lutz, http://www.streetinsider.com/Business+Wire/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html Mon, 08 Jun 2026 16:05:00 -0400 A.05438480 A.41475125 A.50213484 O.00674119 O.01272850 O.02190753 O.35924857 SVRA Savara Announces Chief Financial and Administrative Officer Transition http://www.streetinsider.com/Business+Wire/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html <p class="bwalignc"> <i>-- Dave Lowrance to Step Down as Chief Financial and Administrative Officer --</i> </p><p class="bwalignc"> <i>-- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=Savara+Inc.&index=1&md5=fd315673be183a0a0a21a0d8d4f2e327" shape="rect">Savara Inc.</a> (Nasdaq: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=SVRA&index=2&md5=c334f87372219b3a62213808dc7dc0cb" shape="rect">SVRA</a>) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of this transition, the financial and administrative responsibilities of the role will be separated going forward. Robert Lutz, http://www.streetinsider.com/Business+Wire/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html Mon, 08 Jun 2026 16:05:00 -0400 A.05438480 A.41475125 A.50213484 O.00674119 O.01272850 O.02190753 O.35924857 SVRA Savara Announces Chief Financial and Administrative Officer Transition http://www.streetinsider.com/Business+Wire/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html <p class="bwalignc"> <i>-- Dave Lowrance to Step Down as Chief Financial and Administrative Officer --</i> </p><p class="bwalignc"> <i>-- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=Savara+Inc.&index=1&md5=fd315673be183a0a0a21a0d8d4f2e327" shape="rect">Savara Inc.</a> (Nasdaq: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=SVRA&index=2&md5=c334f87372219b3a62213808dc7dc0cb" shape="rect">SVRA</a>) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of this transition, the financial and administrative responsibilities of the role will be separated going forward. Robert Lutz, http://www.streetinsider.com/Business+Wire/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html Mon, 08 Jun 2026 16:05:00 -0400 A.05438480 A.41475125 A.50213484 O.00674119 O.01272850 O.02190753 O.35924857 SVRA Savara Announces Chief Financial and Administrative Officer Transition http://www.streetinsider.com/Business+Wire/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html <p class="bwalignc"> <i>-- Dave Lowrance to Step Down as Chief Financial and Administrative Officer --</i> </p><p class="bwalignc"> <i>-- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=Savara+Inc.&index=1&md5=fd315673be183a0a0a21a0d8d4f2e327" shape="rect">Savara Inc.</a> (Nasdaq: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=SVRA&index=2&md5=c334f87372219b3a62213808dc7dc0cb" shape="rect">SVRA</a>) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of this transition, the financial and administrative responsibilities of the role will be separated going forward. Robert Lutz, http://www.streetinsider.com/Business+Wire/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html Mon, 08 Jun 2026 16:05:00 -0400 A.05438480 A.41475125 A.50213484 O.00674119 O.01272850 O.02190753 O.35924857 SVRA Savara Announces Chief Financial and Administrative Officer Transition http://www.streetinsider.com/Business+Wire/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html <p class="bwalignc"> <i>-- Dave Lowrance to Step Down as Chief Financial and Administrative Officer --</i> </p><p class="bwalignc"> <i>-- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=Savara+Inc.&index=1&md5=fd315673be183a0a0a21a0d8d4f2e327" shape="rect">Savara Inc.</a> (Nasdaq: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=SVRA&index=2&md5=c334f87372219b3a62213808dc7dc0cb" shape="rect">SVRA</a>) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of this transition, the financial and administrative responsibilities of the role will be separated going forward. Robert Lutz, http://www.streetinsider.com/Business+Wire/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html Mon, 08 Jun 2026 16:05:00 -0400 A.05438480 A.41475125 A.50213484 O.00674119 O.01272850 O.02190753 O.35924857 SVRA Savara Announces Chief Financial and Administrative Officer Transition http://www.streetinsider.com/Business+Wire/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html <p class="bwalignc"> <i>-- Dave Lowrance to Step Down as Chief Financial and Administrative Officer --</i> </p><p class="bwalignc"> <i>-- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer --</i> </p> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=Savara+Inc.&index=1&md5=fd315673be183a0a0a21a0d8d4f2e327" shape="rect">Savara Inc.</a> (Nasdaq: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54549056&newsitemid=20260608876987&lan=en-US&anchor=SVRA&index=2&md5=c334f87372219b3a62213808dc7dc0cb" shape="rect">SVRA</a>) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of this transition, the financial and administrative responsibilities of the role will be separated going forward. Robert Lutz, http://www.streetinsider.com/Business+Wire/Savara+Announces+Chief+Financial+and+Administrative+Officer+Transition/26617209.html Mon, 08 Jun 2026 16:05:00 -0400 A.05438480 A.41475125 A.50213484 O.00674119 O.01272850 O.02190753 O.35924857 SVRA Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference http://www.streetinsider.com/Press+Releases/Savara+Announces+Participation+in+the+2026+Jefferies+Global+Healthcare+Conference/26557718.html <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54542901&newsitemid=20260527034505&lan=en-US&anchor=Savara+Inc.&index=1&md5=8d57ecde678b2530c53c89576a15439e" shape="rect">Savara Inc.</a> (Nasdaq: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2F&esheet=54542901&newsitemid=20260527034505&lan=en-US&anchor=SVRA&index=2&md5=0749b37d6b85289a70fa81ed1c003cda" shape="rect">SVRA</a>) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will host one-on-one meetings and participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3rd at 11:05am ET in New York, NY. </p><p> The live webcast and subsequent replay will be available on the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestors.savarapharma.com%2Fevents-and-presentations%2Fdefault.aspx&esheet=54542901&newsitemid=20260527034505&lan=en-US&anchor=%26%238220%3BEvents+%26amp%3B+Presentations%26%238221%3B&index=3&md5=3df9f083ef3aa3cfba16f75ddc18e58d" shape="rect">“Events & Presentations”</a> section of the Company’s corporate website and will be archived for 90 days. </p><p> <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsavarapharma.com%2Fabout-savara%2Four-company%2F&esheet=54542901&newsitemid=20260527034505&lan=en-US&anchor=About+Savara&index=4&md5=24a33198220b053d04dc38d9b97d7ab7" shape="rect"><b>About http://www.streetinsider.com/Press+Releases/Savara+Announces+Participation+in+the+2026+Jefferies+Global+Healthcare+Conference/26557718.html Wed, 27 May 2026 16:05:00 -0400 O.01272850 SVRA